Delivering gene therapies to the brain is one of the toughest challenges in biotech. But what if we could hijack the body’s own transport system to do it?

In this episode, we dive into a 2016 study on exosome-associated AAV vectors; a clever fusion that improves AAV delivery to the central nervous system. By packaging AAVs inside naturally occurring exosomes, researchers demonstrated enhanced transduction efficiency across the blood-brain barrier, with reduced immune response and broader tissue reach.

We explore the mechanisms, the implications for non-invasive CNS gene therapy, and what this means for future treatments in neurology and beyond.

Featured Article: Exosome-Associated AAV Vector as a Robust and Convenient Neuroscience Tool (https://pubmed.ncbi.nlm.nih.gov/26836117/)